Candriam SCA’s Perspective Therapeutics CATX Stock Holding History

Candriam SCA’s Portfolio CATX Stock Details CATX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-3,488	Closed	-$28K	–	883
2021 Q2	$28K	Buy	+3,488	New	+$30.5K	﹤0.01%	852

Other funds holding CATX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HPWM

Highland Private Wealth Management Bellevue, Washington $620M AUM 18.88% 1-Year Est. Return

Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Candriam SCA's CATX Position: Q3 2021 in Review

Candriam SCA sold out of Perspective Therapeutics (CATX) in Q3 2021, closing a stake of 3,488 shares — an estimated $28K sold.

Candriam SCA first reported a position in CATX in Q2 2021 and held it in 1 quarter. The position peaked at $28K in Q2 2021. 43 funds tracked by Wall St. Rank hold CATX as of Q3 2021.

Candriam SCA reported no remaining Perspective Therapeutics position as of Q3 2021 after selling out during the quarter.
Candriam SCA sold 3,488 Perspective Therapeutics shares in Q3 2021, an estimated $28K.
Candriam SCA first reported a position in Perspective Therapeutics in Q2 2021 and held it in 1 quarter.
Candriam SCA's Perspective Therapeutics position peaked at $28K in Q2 2021.
43 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q3 2021.

Based on Candriam SCA's 13F filing for Q3 2021, filed 9 Nov 2021.